11 results about "Streptococcus pneumoniae serotype" patented technology

This invention relates to novel immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular glycoantigens (glycoconjugates) and their uses. The immunogenic compositions of this invention will generally comprise at least one glycoconjugate derived from a Streptococcus pneumoniae serotype not found in Prevnar, Synflorix, and / or Prevnar 13. This invention also relates to the use of said novel immunogenic compositions for the vaccination of human subjects, particularly infants and the elderly, against pneumococcal infection.

The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to sized Streptococcus pneumoniae serotype 6A capsular polysaccharides, in particular Streptococcus pneumoniae serotype 6A capsular polysaccharides having the average size (e.g. Mw) of the Streptococcus pneumoniae serotype 6A capsular polysaccharide is between 100-1000 kDa, suitably conjugated to a carrier protein.

The present invention relates to novel immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising such immunogenic compositions and uses thereof. The immunogenic compositions of the present invention will generally comprise at least one glycoconjugate from Streptococcus pneumoniae serotypes that are not present and / or in. The invention also relates to vaccination of human individuals, especially infants and elderly people, against Streptococcus pneumoniae infection using such novel immunogenic compositions.

The present invention provides a method of producing a polysaccharide-protein conjugate with capsular polysaccharide from Streptococcus pneumoniae serotype 19F conjugated to a carrier protein. The method includes a prolonged incubation step prior to filtration to remove free polysaccharide.

The present invention relates to new vaccine formulations comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Vaccine formulations of the invention typically comprise at least one glycoconjugate from an S. pneumoniae serotype in a formulation designed to facilitate resuspension. [Figure 1] TIFF2025541706000005.tif58160

The present invention relates to a novel immunogenic composition containing a conjugated Streptococcus pneumoniae capsular sugar antigen (sugar conjugate), a kit containing the immunogenic composition, and the use of the same. The immunogenic composition of the present invention typically contains at least one sugar conjugate derived from a Streptococcus pneumoniae serotype not found in PREVNAR®, SYNFLORIX®, and / or PREVNAR13®. The present invention also relates to the vaccination of human subjects, particularly infants and the elderly, against pneumococcal infection using the novel immunogenic composition.

The present invention relates to novel immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. The immunogenic compositions of the present invention generally comprise glycoconjugates of at least one Streptococcus pneumoniae serotype not found in and / or in. The invention also relates to vaccination of human subjects, in particular infants and elderly people, against Streptococcus pneumoniae infection using said novel immunogenic compositions.

The invention discloses a streptococcus pneumoniae protein vaccine. The protein vaccine provided by the invention is selected from a protein derived from Streptococcus pneumoniae from any one of the following (i) to (iii): (i) PBP1A protein and / or a mutant of the PBP1A protein and / or a mutant of the PBP1A protein and / or a mutant of the PBP1A protein and / or a mutant of the PBP1A protein and / or the mutant of the PBP1A protein and / or the mutant of the PBP1A protein; (ii) a combination of a PBP1A protein and / or a mutant thereof with at least one of a PhtE protein and / or a mutant thereof, a CbpA protein and / or a mutant thereof, a PspA protein and / or a mutant thereof, and an RrgA protein and / or a mutant thereof; (iii) a first fusion protein and / or a mutant thereof, a second fusion protein and / or a mutant thereof, a PhtE protein and / or a mutant thereof, and a PdB protein and / or a mutant thereof. The vaccine provided by the invention has a protective effect on various streptococcus pneumoniae serotypes.

The invention is directed to an immunogenic composition comprising one or more conjugated bacterial capsular polysaccharides derived from Streptococcus pneumoniae serotypes, a saponin-based adjuvant, and a pharmaceutically acceptable carrier. The invention includes a method of preventing, treating or ameliorating a Streptococcus pneumoniae infection, disease or condition in a subject, comprising administering to the subject an effective amount of an immunogenic composition comprising one or more conjugated bacterial capsular polysaccharides derived from Streptococcus pneumoniae serotypes, a saponin-based adjuvant, and a pharmaceutically acceptable carrier.

Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid (TT) or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of two of serotypes 1, 3, and 5 and one or both of serotypes 15B and 22F are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM197. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.